D. Lavanchy, Evolving epidemiology of hepatitis C virus, Clinical Microbiology and Infection, vol.17, issue.2, pp.107-115, 2011.
DOI : 10.1111/j.1469-0691.2010.03432.x

C. Shepard, L. Finelli, and M. Alter, Global epidemiology of hepatitis C virus infection, The Lancet Infectious Diseases, vol.5, issue.9, pp.558-567, 2005.
DOI : 10.1016/S1473-3099(05)70216-4

J. Mchutchison, G. Everson, S. Gordon, I. Jacobson, M. Sulkowski et al., Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.360, issue.18, pp.1827-1838, 2009.
DOI : 10.1056/NEJMoa0806104

F. Poordad, J. Mccone, . Jr, B. Bacon, S. Bruno et al., Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011.
DOI : 10.1056/NEJMoa1010494

URL : https://hal.archives-ouvertes.fr/hal-00867494

. Guidance, Chronic hepatitis C virus infection: developing direct-acting antiviral agents for treatment. Rockville, MD: Food and Drug Administration, 2010.

J. Guedj and A. Perelson, Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration, Hepatology, vol.376, issue.6, pp.1801-1808, 2011.
DOI : 10.1002/hep.24272

O. Lenz, J. De-bruijne, L. Vijgen, T. Verbinnen, C. Weegink et al., Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus???Infected Patients Following TMC435 Monotherapy, Gastroenterology, vol.143, issue.5, pp.1176-1178, 2012.
DOI : 10.1053/j.gastro.2012.07.117

J. Guedj, H. Dahari, L. Rong, N. Sansone, R. Nettles et al., Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life, Proceedings of the National Academy of Sciences, vol.110, issue.10, pp.1103991-3996
DOI : 10.1073/pnas.1203110110

R. Thiébaut, J. Guedj, H. Jacqmin-gadda, G. Chêne, P. Trimoulet et al., Estimation of dynamical model parameters taking into account undetectable marker values, BMC Medical Research Methodology, vol.49, issue.1, p.38, 2006.
DOI : 10.1111/1467-9876.00207

J. Guedj, C. Bazzoli, A. Neumann, and F. Mentré, Design evaluation and optimization for models of hepatitis C viral dynamics, Statistics in Medicine, vol.38, issue.18, pp.1045-1056, 2011.
DOI : 10.1002/sim.4191

URL : https://hal.archives-ouvertes.fr/inserm-00615142

H. Wu, A. Ding, D. Gruttola, and V. , Estimation of HIV dynamic parameters, pp.2463-2485, 1998.

J. Hing, S. Woolfrey, D. Greenslade, and P. Wright, Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.465-479, 2001.
DOI : 10.1023/A:1012247131190

V. Duval and M. Karlsson, Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model, Pharmaceutical Research, vol.19, issue.12, pp.1835-1840, 2002.
DOI : 10.1023/A:1021441407898

J. Bertrand, E. Comets, M. Chenel, and F. Mentré, Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models, Biometrics, vol.21, issue.1, pp.146-155, 2012.
DOI : 10.1111/j.1541-0420.2011.01665.x

URL : https://hal.archives-ouvertes.fr/inserm-00709820

A. Neumann, N. Lam, H. Dahari, D. Gretch, T. Wiley et al., Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy, Science, vol.282, issue.5386, pp.103-107, 1998.
DOI : 10.1126/science.282.5386.103

J. Guedj, H. Dahari, R. Pohl, P. Ferenci, and A. Perelson, Understanding silibinin???s modes of action against HCV using viral kinetic modeling, Journal of Hepatology, vol.56, issue.5, pp.1019-1024, 2012.
DOI : 10.1016/j.jhep.2011.12.012

E. Shudo, R. Ribeiro, A. Talal, and A. Perelson, A hepatitis C viral kinetic model that allows for time-varying drug effectiveness, Antivir Ther, vol.13, pp.919-926, 2008.

K. Matsuura, Y. Tanaka, I. Hasegawa, T. Ohno, H. Tokuda et al., Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients, Journal of Clinical Microbiology, vol.47, issue.2, pp.385-389, 2009.
DOI : 10.1128/JCM.01753-08

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005.
DOI : 10.1016/j.csda.2004.07.002

S. Beal, Ways to fit a PK model with some data below the quantification limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001.
DOI : 10.1023/A:1012299115260

A. Samson, M. Lavielle, and F. Mentré, Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-1574, 2006.
DOI : 10.1016/j.csda.2006.05.007

URL : https://hal.archives-ouvertes.fr/inserm-00182360

A. Dubois, M. Lavielle, S. Gsteiger, E. Pigeolet, and F. Mentré, Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm, Statistics in Medicine, vol.50, pp.2582-2600, 2011.
DOI : 10.1002/sim.4286

URL : https://hal.archives-ouvertes.fr/inserm-00643832

J. Bertrand, E. Comets, C. Laffont, M. Chenel, and F. Mentré, Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.4, pp.317-339, 2009.
DOI : 10.1007/s10928-009-9124-x

URL : https://hal.archives-ouvertes.fr/inserm-00406739

S. Retout, E. Comets, A. Samson, and F. Mentré, Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, pp.5162-5179, 2007.
DOI : 10.1002/sim.2910

URL : https://hal.archives-ouvertes.fr/hal-00263513

S. Retout and F. Mentré, Optimization of Individual and Population Designs Using Splus, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.6, pp.417-443, 2003.
DOI : 10.1023/B:JOPA.0000013000.59346.9a

E. Snoeck, P. Chanu, M. Lavielle, P. Jacqmin, E. Jonsson et al., A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure, Clinical Pharmacology & Therapeutics, vol.308, issue.6, pp.706-713, 2010.
DOI : 10.1016/j.csda.2004.07.002

URL : https://hal.archives-ouvertes.fr/hal-00637434

L. Rong, H. Dahari, R. Ribeiro, and A. Perelson, Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus, Science Translational Medicine, vol.2, issue.30, pp.30-32, 2010.
DOI : 10.1126/scitranslmed.3000544

A. Chatterjee, J. Guedj, and A. Perelson, Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?, Antiviral Therapy, vol.17, issue.6 Pt B, pp.1171-1182, 2012.
DOI : 10.3851/IMP2428

B. Adiwijaya, B. Hare, P. Caron, J. Randle, A. Neumann et al., Rapid decrease of wild-type hepatitis C virus on telaprevir treatment, Antivir Ther, vol.14, pp.591-595, 2009.